Literature DB >> 20210727

Other drugs acting on nervous system associated with QT-interval prolongation.

Guillermo Alberto Keller1, Marcelo L Ponte, Guillermo Di Girolamo.   

Abstract

Several drugs acting on the nervous system have been implicated in the prolongation of the QT interval. Leaving aside the antidepressant and antipsychotic drugs, some have shown to prolong the QT interval in vivo. These include opioids, particularly methadone, inhalational anesthetics, and some preparations used for treatment of cough. These drugs have a narrow therapeutic interval or possible drug interactions that lead to clinical toxicity manifested by arrhythmias. They share the ability to block potassium channels (HERG), prolong the action potential and QT interval, and generate arrhythmias and Torsades de Pointes like other typicality recognized like antiarrhythmics, antihistamines, prokinetics, psychotropics and anti-infectives agents. Muscle relaxants like alcuronium, pancuronium and atracurium associated with or without atropine prolong significantly the QT interval. Methadone is the opiod most tightly associated with QTc prolongation; with much lesser potency buprenorphine and oxycodone can block HERG channels and depress the IKr current in vitro.Antineoplastic chemotherapy like anthracyclines, alkylating drugs, alkilants and cisplatin are associated with electrocardiographic alterations including prolongation of QT and emesis of different grades. It's very important take in account the synergic effects over the QT prolongation when effective antiemetics like 5-HT3 receptor antagonist (granisetron, ondansetron, and dolasetron) are administered. The Knowledge of their pharmacological properties is of vital importance to avoid exposing particularly vulnerable individuals as those with congenital long QT syndrome, and even the general public to unnecessary risk of potentially fatal arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20210727     DOI: 10.2174/157488610789869256

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  12 in total

1.  Dose-specific adverse drug reaction identification in electronic patient records: temporal data mining in an inpatient psychiatric population.

Authors:  Robert Eriksson; Thomas Werge; Lars Juhl Jensen; Søren Brunak
Journal:  Drug Saf       Date:  2014-04       Impact factor: 5.606

Review 2.  QT interval abnormalities: risk factors and perioperative management in long QT syndromes and Torsades de Pointes.

Authors:  Alan David Kaye; Jacqueline Volpi-Abadie; J Michael Bensler; Adam M Kaye; James H Diaz
Journal:  J Anesth       Date:  2013-02-15       Impact factor: 2.078

Review 3.  State of the Art Antiemetic Therapy for Cancer Patients.

Authors:  Thomas K H Lau; Claudia H W Yip; Winnie Yeo
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.075

Review 4.  Ion channel trafficking: a new therapeutic horizon for atrial fibrillation.

Authors:  Sarah M Schumacher; Jeffrey R Martens
Journal:  Heart Rhythm       Date:  2010-02-13       Impact factor: 6.343

5.  Ondansetron causing near fatal catastrophe in a renal transplant recipient.

Authors:  Sandeep Sahu; Sunaina Tejpal Karna; Anil Agarwal; Sushil Prakash Ambesh; Aneesh Srivastava
Journal:  Indian J Anaesth       Date:  2011-01

6.  Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study.

Authors:  Matthew J Hafermann; Rocsanna Namdar; Gretchen E Seibold; Robert Lee Page
Journal:  Drug Healthc Patient Saf       Date:  2011-10-03

7.  Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy.

Authors:  S Michael Roberts; Dmitri S Bezinover; Piotr K Janicki
Journal:  Cancer Manag Res       Date:  2012-02-24       Impact factor: 3.989

8.  Impact of inhomogeneous static magnetic field (31.7-232.0 mT) exposure on human neuroblastoma SH-SY5Y cells during cisplatin administration.

Authors:  Cristian Vergallo; Meysam Ahmadi; Hamid Mobasheri; Luciana Dini
Journal:  PLoS One       Date:  2014-11-25       Impact factor: 3.240

9.  Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects.

Authors:  Ana-Maria Florea; Dietrich Büsselberg
Journal:  Cancers (Basel)       Date:  2011-03-15       Impact factor: 6.639

Review 10.  Pain medication and long QT syndrome.

Authors:  Christoph Klivinyi; Helmar Bornemann-Cimenti
Journal:  Korean J Pain       Date:  2018-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.